Table 1 Patient survival, graft survival and renal function with and without imputation for missing values at 12 and 24 months after conversion to belatacept. GFR 9 mL/min was imputed for kidney graft loss
|  | Switch to belatacept (N = 30) GFR at switch = 22.5 ± 12 mL/min | Control cohort (N = 56) GFR at start of observation = 24.5 ± 14 mL/min | ||
|---|---|---|---|---|
Timepoint after switch | 12 months | 24 months | 12 months | 24 months |
Patient survival | 96.7% (29/30) | 90% (27/30) | 96.4% (54/56) | 91.07% (51/56) |
Death with functioning graft | 1/30 | 3/30 | 2/56 | 5/56 |
Kidney or pancreas graft loss | 6/30 | 9/30 | 8/56 | 16/56 |
Death-censored kidney graft survival | 79.3% (23/29) | 66.7% (18/27) | 85.2% (46/54) | 68.6% (35/51) |
Overall kidney graft survival | 76.7% (23/30) | 60.0% (18/30) | 82.1% (46/56) | 62.5% (35/56) |
Median GFR in patients without graft loss | 23.3 ± 15 | 24.5 ± 15.0 | 23.0 ± 15 | 24.0 ± 9 |
ΔGFR from GFR at baseline in patients without graft loss | 1.3 ± 5.9 | 1.8 ± 7.9 | −2.0 ± 7.2 | − 3.5 ± 8.6 |
Median GFR with imputation for graft loss | 21.5 ± 18 | 18.5 ± 21 | 21.5 ± 18 | 19 ± 17 |
ΔGFR from GFR at baseline in patients with imputation for graft loss | −0.56 ± 6.8 | − 1.54 ± 8.4 | −3.3 ± 7.6 | −5.5 ± 8.3 |